Antiphospholipid antibody: laboratory, pathogenesis and clinical manifestations
Abstract
Antiphospholipid antibodies (aPL) represent a heterogeneous group of antibodies that recognize various antigenic targets including beta2 glycoprotein I (β2GPI), prothrombin (PT), activated protein C, tissue plasminogen activator, plasmin and annexin A2. The most commonly used tests to detect aPL are: lupus anticoagulant (LAC), a functional coagulation assay, anticardiolipin antibody (aCL) and anti-β2GPI antibody (anti-β2GPI), which are enzyme-linked immunoassay (ELISA). Clinically aPL are associated with thrombosis and/or with pregnancy morbidity. Apparently aPL alone are unable to induce thrombotic manifestations, but they increase the risk of vascular events that can occur in the presence of another thrombophilic condition; on the other hand obstetrical manifestations were shown to be associated not only to thrombosis but mainly to a direct antibody effect on the trophoblast.Downloads
Download data is not yet available.
Statistics
- Abstract views: 1343
- PDF: 2529
How to Cite
Tincani, A., Casu, C., Cartella, S., Ziglioli, T., & Cattaneo, R. (1). Antiphospholipid antibody: laboratory, pathogenesis and clinical manifestations. Reumatismo, 62(1), 65-75. https://doi.org/10.4081/reumatismo.2010.65
Copyright (c) 1970 A. Tincani, C. Casu, S. Cartella, T. Ziglioli, R. Cattaneo

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.